C-reactive protein is a mediator of cardiovascular disease
C-reactive protein is postulated to embody an index that can reflect cardiovascular risk and can be used to independently predict major cardiovascular events and mortality. On the other hand, credible experimental data have become available that demonstrate the abundant presence of C-reactive protei...
Gespeichert in:
| Veröffentlicht in: | European heart journal 2010-09, Vol.31 (17), p.2087-2091 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2091 |
|---|---|
| container_issue | 17 |
| container_start_page | 2087 |
| container_title | European heart journal |
| container_volume | 31 |
| creator | Bisoendial, Radjesh J. Boekholdt, S. Matthijs Vergeer, Menno Stroes, Erik S.G. Kastelein, John J.P. |
| description | C-reactive protein is postulated to embody an index that can reflect cardiovascular risk and can be used to independently predict major cardiovascular events and mortality. On the other hand, credible experimental data have become available that demonstrate the abundant presence of C-reactive protein in atherosclerotic lesions and, moreover, identify C-reactive protein as an initiator of several pathogenic pathways that can cause atherogenic changes. Consequently, there has been a paradigm shift in which C-reactive protein is no longer regarded as merely an indicator of cardiovascular risk, but increasingly considered a direct partaker in the pathogenesis of atherosclerotic cardiovascular disease. These data underscore the need to explore risk-reducing interventions that selectively inhibit C-reactive protein activity as a novel strategy to prevent clinical manifestations of atherosclerosis. |
| doi_str_mv | 10.1093/eurheartj/ehq238 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754000065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>754000065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-e17376a5f351db84bc9da13365dc969460c65eec48b08d1c7be452ace2f428c93</originalsourceid><addsrcrecordid>eNpFkMtLxDAQh4Mouj7unqQX8VTNu6k3WR8rKoIoLF7CNJ1itLvVpBX9743sup7mMN88fh8h-4weM1qKExzCC0LoX0_w5YMLs0ZGTHGel1qqdTKirFS51ma6RbZjfKWUGs30JtniVBulDR-R03EeEFzvPzF7D12Pfp75mEE2w9pD34WsazIHofbdJ0Q3tBCy2keEiLtko4E24t6y7pCny4vH8SS_vb-6Hp_d5k4Wss-RFaLQoBqhWF0ZWbmyBiaEVrUrdSk1dVohOmkqamrmigql4uCQN5IbV4odcrTYm_77GDD2duajw7aFOXZDtIWSKRnVKpF0QbrQxRiwse_BzyB8W0btrzC7EmYXwtLIwXL5UKXIq4E_Qwk4XAIpPrRNgLnz8Z8TnP-eT1y-4Hzs8WvVh_BmdRKg7GT6bC_vJs83D-dTOxY_hmKGNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>754000065</pqid></control><display><type>article</type><title>C-reactive protein is a mediator of cardiovascular disease</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Bisoendial, Radjesh J. ; Boekholdt, S. Matthijs ; Vergeer, Menno ; Stroes, Erik S.G. ; Kastelein, John J.P.</creator><creatorcontrib>Bisoendial, Radjesh J. ; Boekholdt, S. Matthijs ; Vergeer, Menno ; Stroes, Erik S.G. ; Kastelein, John J.P.</creatorcontrib><description>C-reactive protein is postulated to embody an index that can reflect cardiovascular risk and can be used to independently predict major cardiovascular events and mortality. On the other hand, credible experimental data have become available that demonstrate the abundant presence of C-reactive protein in atherosclerotic lesions and, moreover, identify C-reactive protein as an initiator of several pathogenic pathways that can cause atherogenic changes. Consequently, there has been a paradigm shift in which C-reactive protein is no longer regarded as merely an indicator of cardiovascular risk, but increasingly considered a direct partaker in the pathogenesis of atherosclerotic cardiovascular disease. These data underscore the need to explore risk-reducing interventions that selectively inhibit C-reactive protein activity as a novel strategy to prevent clinical manifestations of atherosclerosis.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehq238</identifier><identifier>PMID: 20685682</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Atherosclerosis - drug therapy ; Atherosclerosis - epidemiology ; Atherosclerosis - etiology ; Biological and medical sciences ; Blood Coagulation - physiology ; C-reactive protein ; C-Reactive Protein - physiology ; Cardiology. Vascular system ; Complement System Proteins - physiology ; Coronary Disease - drug therapy ; Coronary Disease - epidemiology ; Coronary Disease - etiology ; Endothelium, Vascular ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Male ; Medical sciences ; Plaque, Atherosclerotic - pathology ; Randomized Controlled Trials as Topic</subject><ispartof>European heart journal, 2010-09, Vol.31 (17), p.2087-2091</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-e17376a5f351db84bc9da13365dc969460c65eec48b08d1c7be452ace2f428c93</citedby><cites>FETCH-LOGICAL-c474t-e17376a5f351db84bc9da13365dc969460c65eec48b08d1c7be452ace2f428c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23224000$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20685682$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bisoendial, Radjesh J.</creatorcontrib><creatorcontrib>Boekholdt, S. Matthijs</creatorcontrib><creatorcontrib>Vergeer, Menno</creatorcontrib><creatorcontrib>Stroes, Erik S.G.</creatorcontrib><creatorcontrib>Kastelein, John J.P.</creatorcontrib><title>C-reactive protein is a mediator of cardiovascular disease</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description>C-reactive protein is postulated to embody an index that can reflect cardiovascular risk and can be used to independently predict major cardiovascular events and mortality. On the other hand, credible experimental data have become available that demonstrate the abundant presence of C-reactive protein in atherosclerotic lesions and, moreover, identify C-reactive protein as an initiator of several pathogenic pathways that can cause atherogenic changes. Consequently, there has been a paradigm shift in which C-reactive protein is no longer regarded as merely an indicator of cardiovascular risk, but increasingly considered a direct partaker in the pathogenesis of atherosclerotic cardiovascular disease. These data underscore the need to explore risk-reducing interventions that selectively inhibit C-reactive protein activity as a novel strategy to prevent clinical manifestations of atherosclerosis.</description><subject>Atherosclerosis - drug therapy</subject><subject>Atherosclerosis - epidemiology</subject><subject>Atherosclerosis - etiology</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation - physiology</subject><subject>C-reactive protein</subject><subject>C-Reactive Protein - physiology</subject><subject>Cardiology. Vascular system</subject><subject>Complement System Proteins - physiology</subject><subject>Coronary Disease - drug therapy</subject><subject>Coronary Disease - epidemiology</subject><subject>Coronary Disease - etiology</subject><subject>Endothelium, Vascular</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Plaque, Atherosclerotic - pathology</subject><subject>Randomized Controlled Trials as Topic</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtLxDAQh4Mouj7unqQX8VTNu6k3WR8rKoIoLF7CNJ1itLvVpBX9743sup7mMN88fh8h-4weM1qKExzCC0LoX0_w5YMLs0ZGTHGel1qqdTKirFS51ma6RbZjfKWUGs30JtniVBulDR-R03EeEFzvPzF7D12Pfp75mEE2w9pD34WsazIHofbdJ0Q3tBCy2keEiLtko4E24t6y7pCny4vH8SS_vb-6Hp_d5k4Wss-RFaLQoBqhWF0ZWbmyBiaEVrUrdSk1dVohOmkqamrmigql4uCQN5IbV4odcrTYm_77GDD2duajw7aFOXZDtIWSKRnVKpF0QbrQxRiwse_BzyB8W0btrzC7EmYXwtLIwXL5UKXIq4E_Qwk4XAIpPrRNgLnz8Z8TnP-eT1y-4Hzs8WvVh_BmdRKg7GT6bC_vJs83D-dTOxY_hmKGNA</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Bisoendial, Radjesh J.</creator><creator>Boekholdt, S. Matthijs</creator><creator>Vergeer, Menno</creator><creator>Stroes, Erik S.G.</creator><creator>Kastelein, John J.P.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100901</creationdate><title>C-reactive protein is a mediator of cardiovascular disease</title><author>Bisoendial, Radjesh J. ; Boekholdt, S. Matthijs ; Vergeer, Menno ; Stroes, Erik S.G. ; Kastelein, John J.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-e17376a5f351db84bc9da13365dc969460c65eec48b08d1c7be452ace2f428c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Atherosclerosis - drug therapy</topic><topic>Atherosclerosis - epidemiology</topic><topic>Atherosclerosis - etiology</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation - physiology</topic><topic>C-reactive protein</topic><topic>C-Reactive Protein - physiology</topic><topic>Cardiology. Vascular system</topic><topic>Complement System Proteins - physiology</topic><topic>Coronary Disease - drug therapy</topic><topic>Coronary Disease - epidemiology</topic><topic>Coronary Disease - etiology</topic><topic>Endothelium, Vascular</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Plaque, Atherosclerotic - pathology</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bisoendial, Radjesh J.</creatorcontrib><creatorcontrib>Boekholdt, S. Matthijs</creatorcontrib><creatorcontrib>Vergeer, Menno</creatorcontrib><creatorcontrib>Stroes, Erik S.G.</creatorcontrib><creatorcontrib>Kastelein, John J.P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bisoendial, Radjesh J.</au><au>Boekholdt, S. Matthijs</au><au>Vergeer, Menno</au><au>Stroes, Erik S.G.</au><au>Kastelein, John J.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C-reactive protein is a mediator of cardiovascular disease</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>31</volume><issue>17</issue><spage>2087</spage><epage>2091</epage><pages>2087-2091</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>C-reactive protein is postulated to embody an index that can reflect cardiovascular risk and can be used to independently predict major cardiovascular events and mortality. On the other hand, credible experimental data have become available that demonstrate the abundant presence of C-reactive protein in atherosclerotic lesions and, moreover, identify C-reactive protein as an initiator of several pathogenic pathways that can cause atherogenic changes. Consequently, there has been a paradigm shift in which C-reactive protein is no longer regarded as merely an indicator of cardiovascular risk, but increasingly considered a direct partaker in the pathogenesis of atherosclerotic cardiovascular disease. These data underscore the need to explore risk-reducing interventions that selectively inhibit C-reactive protein activity as a novel strategy to prevent clinical manifestations of atherosclerosis.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>20685682</pmid><doi>10.1093/eurheartj/ehq238</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2010-09, Vol.31 (17), p.2087-2091 |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754000065 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Atherosclerosis - drug therapy Atherosclerosis - epidemiology Atherosclerosis - etiology Biological and medical sciences Blood Coagulation - physiology C-reactive protein C-Reactive Protein - physiology Cardiology. Vascular system Complement System Proteins - physiology Coronary Disease - drug therapy Coronary Disease - epidemiology Coronary Disease - etiology Endothelium, Vascular Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Medical sciences Plaque, Atherosclerotic - pathology Randomized Controlled Trials as Topic |
| title | C-reactive protein is a mediator of cardiovascular disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A11%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C-reactive%20protein%20is%20a%20mediator%20of%20cardiovascular%20disease&rft.jtitle=European%20heart%20journal&rft.au=Bisoendial,%20Radjesh%20J.&rft.date=2010-09-01&rft.volume=31&rft.issue=17&rft.spage=2087&rft.epage=2091&rft.pages=2087-2091&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehq238&rft_dat=%3Cproquest_cross%3E754000065%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=754000065&rft_id=info:pmid/20685682&rfr_iscdi=true |